{"id":533767,"date":"2021-09-02T08:04:46","date_gmt":"2021-09-02T12:04:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/"},"modified":"2021-09-02T08:04:46","modified_gmt":"2021-09-02T12:04:46","slug":"lumos-pharma-to-participate-in-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/","title":{"rendered":"Lumos Pharma to Participate in September Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">AUSTIN, Texas, Sept.  02, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KyUX7YN6ed_s_gCyvKY9k7n1x2-d8ksOEVxQ-Job00Y8mRH5Ke1fa1xSTiMQybuA0sOpptYZok2zdxMQ3_ISKrW4Oo-ltvENxyKBCZ3PUI=\" rel=\"nofollow noopener\" target=\"_blank\">Lumos Pharma, Inc.<\/a>\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23<sup>rd<\/sup> Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:12%;width:12%;min-width:12%;vertical-align: bottom\">Event:<\/td>\n<td style=\"max-width:88%;width:88%;min-width:88%;vertical-align: bottom\">\n            <strong>H.C. Wainwright 23<\/strong><br \/>\n            <sup><br \/>\n              <strong>rd<\/strong><br \/>\n            <\/sup><br \/>\n            <strong> Annual Global Investor Conference \u2013 September 13-15<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Presentation:<\/td>\n<td style=\"vertical-align: bottom\">Pre-recorded presentation available beginning September 13 at 7:00 AM (ET)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Webcast link:<\/td>\n<td style=\"vertical-align: bottom\">\n            <a href=\"https:\/\/journey.ct.events\/view\/faac79c2-c9a2-46cf-9d99-41af321859a8\" rel=\"nofollow noopener\" target=\"_blank\">Here<\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Event:<\/td>\n<td style=\"vertical-align: bottom\">\n            <strong>Cantor Virtual Global Healthcare Conference \u2013 September 27-30<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Presentation:<\/td>\n<td style=\"vertical-align: bottom\">Live fireside chat September 29 from 4:00-4:30 PM (ET)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Webcast link:<\/td>\n<td style=\"vertical-align: bottom\">\n            <a href=\"https:\/\/wsw.com\/webcast\/cantor12\/register.aspx?conf=cantor12&amp;page=lumo&amp;url=https:\/\/wsw.com\/webcast\/cantor12\/lumo\/2107490\" rel=\"nofollow noopener\" target=\"_blank\">Here<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">The webcasts for each presentation can also be found on the Company\u2019s website under \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dykgZeMlizfAWhaAalJvW2_gKjjLtXU7gyPqsahKfizF5dGGHzt9JeKz5FN_jJeJRDSd3aRp5o-6654MPD-7de30Heq1t-lm95Zq7_pov9jXU0kxRyzLKNLtg_uFMBGQ0BQ4bRnmdUY3HaD3ywyl9g==\" rel=\"nofollow noopener\" target=\"_blank\">Events &amp; Presentations<\/a>\u201d in the Investors &amp; Media section where a replay of each presentation will be also be available. Please contact your H.C. Wainwright or Cantor salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.<\/p>\n<p align=\"justify\">\n        <strong>About Lumos Pharma<\/strong>\n      <\/p>\n<p align=\"justify\">Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Sant\u00e9 Ventures, and UCB. Lumos Pharma\u2019s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK\/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NociPRTex-siGTCFP09Q42wqOR5YTlnN51yg8JEPf_1wOqcFS54ucKTjGCQ2Bs8Xqda49FDhRtg9JDWgHdBGH0FURguxug7eoBiZIo94h4k=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/lumos-pharma.com\/<\/a>.<\/p>\n<p>Investor &amp; Media Contact:<\/p>\n<p>Lisa Miller<br \/>Lumos Pharma Investor Relations<br \/>512-792-5454<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H7064AWgDX2ClEiTx1g6lWMdMCdCuxuStzOouEsKMS3G9Rxec7JZ5LgCtggj-ks7yFyo3-FpGaQzdrtZLeFaErF1Ew8o6kSEVqcqsD6oyoE=\" rel=\"nofollow noopener\" target=\"_blank\">ir@lumos-pharma.com<\/a><\/p>\n<p>Source: Lumos Pharma, Inc.<\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/Mjc3MmZlMjMtNzNmYi00ZWQxLTk5MGYtYmUyMzEwYWIxNzZjLTEwMjgxNTA=\/tiny\/Lumos-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Lumos Pharma, Inc.\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September. Event: H.C. Wainwright 23 rd Annual Global Investor Conference \u2013 September 13-15 Presentation: Pre-recorded presentation available beginning September 13 at 7:00 AM (ET) Webcast link: Here Event: Cantor Virtual Global Healthcare Conference \u2013 September 27-30 Presentation: Live fireside chat September 29 from 4:00-4:30 PM (ET) Webcast link: Here The webcasts for each presentation can also be found on the Company\u2019s website under \u201cEvents &amp; Presentations\u201d in the Investors &amp; Media section where a replay of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lumos Pharma to Participate in September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-533767","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lumos Pharma to Participate in September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lumos Pharma to Participate in September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Lumos Pharma, Inc.\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September. Event: H.C. Wainwright 23 rd Annual Global Investor Conference \u2013 September 13-15 Presentation: Pre-recorded presentation available beginning September 13 at 7:00 AM (ET) Webcast link: Here Event: Cantor Virtual Global Healthcare Conference \u2013 September 27-30 Presentation: Live fireside chat September 29 from 4:00-4:30 PM (ET) Webcast link: Here The webcasts for each presentation can also be found on the Company\u2019s website under \u201cEvents &amp; Presentations\u201d in the Investors &amp; Media section where a replay of &hellip; Continue reading &quot;Lumos Pharma to Participate in September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T12:04:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lumos Pharma to Participate in September Investor Conferences\",\"datePublished\":\"2021-09-02T12:04:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/\"},\"wordCount\":336,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/\",\"name\":\"Lumos Pharma to Participate in September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=\",\"datePublished\":\"2021-09-02T12:04:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lumos Pharma to Participate in September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lumos Pharma to Participate in September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Lumos Pharma to Participate in September Investor Conferences - Market Newsdesk","og_description":"AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) &#8212; Lumos Pharma, Inc.\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September. Event: H.C. Wainwright 23 rd Annual Global Investor Conference \u2013 September 13-15 Presentation: Pre-recorded presentation available beginning September 13 at 7:00 AM (ET) Webcast link: Here Event: Cantor Virtual Global Healthcare Conference \u2013 September 27-30 Presentation: Live fireside chat September 29 from 4:00-4:30 PM (ET) Webcast link: Here The webcasts for each presentation can also be found on the Company\u2019s website under \u201cEvents &amp; Presentations\u201d in the Investors &amp; Media section where a replay of &hellip; Continue reading \"Lumos Pharma to Participate in September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T12:04:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lumos Pharma to Participate in September Investor Conferences","datePublished":"2021-09-02T12:04:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/"},"wordCount":336,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/","name":"Lumos Pharma to Participate in September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=","datePublished":"2021-09-02T12:04:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxOTQ0MSM0Mzg2ODU2IzIwMTY1Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lumos Pharma to Participate in September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=533767"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/533767\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=533767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=533767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=533767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}